Inovio Pharmaceuticals, Inc.: financial statements

INONASDAQHealthcare · Pharmaceutical Preparations

Price

$1.76

November 20, 2026Market cap $330M

What Ploutos Investor adds for Inovio Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 21% since Nov 10, 2026, when the 10-Q these figures come from was filed ($1.45 then, $1.76 on Nov 20, 2026). The figures date from before that move.10-Q

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

-72.0% a year over 2 years

Line202320242025Average a year
Revenue $832.0K$217.8K$65.3K-72.0%
Operating income -$144M-$112M-$87M
Net income -$135M-$107M-$85M
Earnings per share -$6.09-$3.95-$1.81
Earnings per share, basic -$6.09-$3.95-$1.81
Margins
Operating margin -17,300.3%-51,616.9%-132,871.3%
Net margin -16,239.9%-49,254.3%-130,000.0%

Financial statements

INO's revenue, profits and cash flows from 2009 to 2022, 14 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2019: License $3.6M, Other Revenue $1.8K, Licensewith Affiliated Entities $235.6K
  • 2020: License $5.2M, Other Revenue $786.9K, Licensewith Affiliated Entities $1.5M
  • 2021: License $902.3K, Other Revenue $627.2K, Licensewith Affiliated Entities $245.3K
Product201920202021Share 2021
License$3.6M$5.2M$902.3K51%
Other Revenue$1.8K$786.9K$627.2K35%
Licensewith Affiliated Entities$235.6K$1.5M$245.3K14%

By segment

INO's revenue by product line from 2016 to 2018, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 11 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$9.4M Leases0.0% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$9.4M

Finance leases

–

Average discount rate
9.0%

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

Operating lease payments by year

Lease liability by year

Leases

INO's leases from 2018 to 2022, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.0%

-21.0 pts

The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Tax credits

+3.2 pts

Change in valuation allowance

-19.4 pts

Uncertain tax positions

-1.8 pts

Share-based compensation

-1.2 pts

Non-deductible expenses

-0.6 pts

Not itemized in the filing

-1.5 pts

Smaller lines (2)

+0.3 pts

Effective rate

0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Effective tax rate by year

Effective tax rate by year

The tax rate INO paid on its profit, from 2011 to 2022, 10 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.

The full analysis

What do Inovio Pharmaceuticals's filings show?

These are Inovio Pharmaceuticals's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about INO's financials

Didn't find what you were looking for?

Ask us
How much revenue did INO have in 2025?

Inovio Pharmaceuticals had revenue of $65.3K and net income of -$85M in fiscal 2025, a net margin of -130,000.0%.

How much debt does INO have?

On December 31, 2025 Inovio Pharmaceuticals had total assets of $74M, debt of – and shareholders' equity of $24M.

How much free cash flow does INO have?

In fiscal 2025 Inovio Pharmaceuticals had cash from operations of -$89M and spent $285.7K on capital expenditure, leaving -$89M of free cash flow.

Where are the figures from?

From Inovio Pharmaceuticals, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.